Kopran Ltd

- Kopran Limited has not taken any new term loans recently; the only existing term loan is related to the Panoli plant taken about 4 years ago, currently around INR10-12 crores. - The remaining debt is mostly working capital, which fluctuates with inventory cycles. - About 30% of the working capital limits remain unused, indicating no immediate need for additional borrowing. - There is no mention of any planned new fundraising through equity or debt in the conference call. - Capex and capacity expansions are being managed within existing financial resources, with no large capex expected in the next 1-2 years. - Any future capex or projects requiring funding will depend on demand and project fruition, but currently, there are no disclosed plans for new fundraising. Hence, Kopran currently has no announced plans for fresh fundraising through equity or debt.

- For the next 1 to 2 years, Kopran Limited does not foresee very large capex, except possibly for setting up vial filling for penems. - Existing capacity is considered sufficient to meet expected demand for the next 2 to 3 years. - In FY '23 and '24, capex was around INR 60 crores each year; capex is expected to significantly reduce in the next couple of years. - Additional capex may be needed if existing projects under consideration materialize and demand increases, requiring dedicated plants. - For formulation businesses, capex remains moderate, around INR 10 crores over 9 months. - The Panoli plant capex is largely completed; commercial production expected to start in Q1 FY '26. - The company is also investing in expanding capacities for growing products like Faropenem and CMO/CDMO projects, which have better margins.

- Target to grow to around INR1,200 crores in the next 3 years through new products and volume increase. - Expect 10%-12% growth in API segment next year, and about 20% growth in the following year. - Consolidated sales growth expected around 15% for FY '26 and 20% for FY '27. - Expansion in CMO and CDMO projects to contribute significantly; aiming for over 50% of business from these in 2 years. - Increased market share in key products like Meropenem (around 20% contribution currently). - Capacity expansions underway at Panoli and Mahad plants to meet increasing demand, with Panoli expected to stabilize next year. - Moving towards higher-margin regulated market projects for sustainable growth and profitability. - Pricing pressure from Chinese competition is stabilizing, with volume growth helping offset price erosion.

- Kopran targets revenue growth to around INR 1,200 crores over the next 3 years, driven by new products and increased volumes benefiting from economies of scale. - EBITDA margins are expected to improve to approximately 17%-20% within 4 years, supported by growth in CMO/CDMO business and operational efficiencies. - Consolidated revenue growth for FY '26 is estimated at about 15% and around 20% for FY '27, reflecting expanded contract manufacturing and API segments. - The CMO and CDMO business is expected to contribute over 50% of revenues in 2 years, providing more consistent and higher-margin earnings. - Capex is expected to be moderate over the next 1-2 years, supporting production capacity expansion mostly in vial filling for penems. - Focus on cost reduction and higher-margin formulations will further underpin profitability improvements.

- Kopran Limited currently has 26 CMO and CDMO projects, either near completion or completed. - Commercial supplies for these projects are expected to start by Q1 FY '26. - An additional 18 CMO and CDMO projects are under implementation, with commercialization expected in stages between 12 to 24 months. - These projects involve a mix of existing and new therapeutic areas, some involving site transfers and new product developments. - The company is entering new CMO and CDMO contracts, aiming to expand this segment further over the next 6 months. - Focus is on regulated markets including the UK and Canada. - Projects include contract manufacturing (CMO) and contract development and manufacturing (CDMO) formulations, mainly based out of the Panoli plant. - The company is prepared to add capacity as demand increases and has enough current manufacturing capacity to meet expected growth in the near term.